MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526695 | Name: LY-344864 free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY-344864 is a potent 5-HT1 receptor agonist.

Chemical Structure

LY-344864 free base
LY-344864 free base
CAS#186544-26-3 (free base)

Theoretical Analysis

MedKoo Cat#: 526695

Name: LY-344864 free base

CAS#: 186544-26-3 (free base)

Chemical Formula: C21H22FN3O

Exact Mass: 351.1747

Molecular Weight: 351.43

Elemental Analysis: C, 71.77; H, 6.31; F, 5.41; N, 11.96; O, 4.55

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,450.00 2 Weeks
1g USD 3,250.00 2 Weeks
2g USD 5,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1217756-94-9 (HCl) 186544-26-3 (free base)
Synonym
LY-344864; LY344864; LY 344864 free base
IUPAC/Chemical Name
N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide
InChi Key
GKWHICIUSVVNGX-MRXNPFEDSA-N
InChi Code
InChI=1S/C21H22FN3O/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26)/t16-/m1/s1
SMILES Code
O=C(NC1=CC2=C(NC3=C2C[C@H](N(C)C)CC3)C=C1)C4=CC=C(F)C=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM.
In vitro activity:
LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. When examined for its ability to inhibit forskolin-induced cyclic AMP accumulation in cells stably transfected with human 5-HT1F receptors, LY344864 was shown to be a full agonist producing an effect similar in magnitude to serotonin itself. Reference: Life Sci. 1997;61(21):2117-26. https://pubmed.ncbi.nlm.nih.gov/9395253/
In vivo activity:
Increased mitochondrial DNA content and nuclear- and mitochondrial-encoded mRNA and protein expression was observed in specific brain regions of LY344864-treated naïve and lesioned mice, indicating augmented MB. LY344864 attenuated TH-ir loss in the striatum and substantia nigra compared to vehicle-treated lesioned animals. LY344864 treatment also increased locomotor activity in 6-hydroxydopamine lesioned mice, while vehicle treatment had no effect. Reference: Br J Pharmacol. 2018 Jan;175(2):348-358. https://pubmed.ncbi.nlm.nih.gov/29057453/
Solvent mg/mL mM
Solubility
DMSO 100.0 284.56
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 351.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bhargava P, Janda J, Schnellmann RG. Elucidation of cGMP-dependent induction of mitochondrial biogenesis through PKG and p38 MAPK in the kidney. Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F322-F328. doi: 10.1152/ajprenal.00533.2019. Epub 2019 Dec 16. PMID: 31841384; PMCID: PMC7052650. 2. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD Jr, Branchek TA, Flaugh ME. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61(21):2117-26. doi: 10.1016/s0024-3205(97)00885-0. PMID: 9395253. 3. Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR. Differential medication overuse risk of novel anti-migraine therapeutics. Brain. 2020 Sep 1;143(9):2681-2688. doi: 10.1093/brain/awaa211. PMID: 32810212; PMCID: PMC7523700. 4. Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG. 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol. 2018 Jan;175(2):348-358. doi: 10.1111/bph.14076. Epub 2017 Dec 22. PMID: 29057453; PMCID: PMC5758398.
In vitro protocol:
1. Bhargava P, Janda J, Schnellmann RG. Elucidation of cGMP-dependent induction of mitochondrial biogenesis through PKG and p38 MAPK in the kidney. Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F322-F328. doi: 10.1152/ajprenal.00533.2019. Epub 2019 Dec 16. PMID: 31841384; PMCID: PMC7052650. 2. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD Jr, Branchek TA, Flaugh ME. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61(21):2117-26. doi: 10.1016/s0024-3205(97)00885-0. PMID: 9395253.
In vivo protocol:
1. Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR. Differential medication overuse risk of novel anti-migraine therapeutics. Brain. 2020 Sep 1;143(9):2681-2688. doi: 10.1093/brain/awaa211. PMID: 32810212; PMCID: PMC7523700. 2. Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG. 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol. 2018 Jan;175(2):348-358. doi: 10.1111/bph.14076. Epub 2017 Dec 22. PMID: 29057453; PMCID: PMC5758398.